oral glp-1 medications Novo Nordisk's drug didn't work on Alzheimer's as hoped, but don't call it a failure FDA Approves Oral Semaglutide: First

The most commonly observed adverse effects in clinical studies are gastrointestinal in nature, consistent with the GLP-1 receptor agonist class

Insulin signaling in arthritis

Larger studies are needed to confirm this, although these would be challenging or infeasible to conduct

Something feels off

How Meltwater Explore+ helps marketers understand platform-specific audience behavior Use Case 1: Identifying platform-specific audience dynamics The insight GLP-1 audiences behave differently across Reddit, X, and Pinterest, making aggregate social listening insufficient for understanding consumer behavior

The approval matters because it validates a long-sought oral small-molecule route to GLP-1 agonism, with potentially major consequences for convenience, manufacturing scale, pricing, and patent strategy